Canadian pancreatic cancer specialist expects to open clinical trials on pill that doubled survival time – CTV
June 03, 2026
TORONTO — The head of pancreatic cancer at Princess Margaret Cancer Centre says she hopes clinical trials for a pill that could double survival time will soon be open to Canadian patients.
Medical oncologist Dr. Jennifer Knox independently reviewed a U.S.-led study of the experimental drug daraxonrasib and calls the results “amazing.”
The randomized Phase 3 clinical trial of 500 pancreatic cancer patients found those who took the daily pill survived for more than a year compared to just over six months for patients who had chemotherapy alone.
Manufacturer Revolution Medicines has applied to the U.S. Food and Drug Administration to license the drug.
Health Canada says it has not received an application to license it in Canada.
Knox says she plans to open clinical trials so as many patients as possible with pancreatic cancer can get the experimental drug without waiting for it to be licensed.
She presented her assessment of the study, which was published in the New England Journal of Medicine, at a meeting of the American Society for Clinical Oncology in Chicago on Sunday.
